drugset / Trial / NCT00348972

Lantus in Prediabetes

NCT00348972

Phase 1 Completed 20 enrolled Sanofi
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the safety, tolerability, and efficacy of Lantus® (insulin glargine) in prediabetes (IFG or IGT).

Timeline

Start
2002-02
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin glargine Protein / enzyme biologic